FH535

Cas No.:	108409-83-2
Chemical Name:	N-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide
Synonyms:	N-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide;FH535;2,5-Dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide;FH-535;FH 535(FH-535);2,5-Dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide FH535;Tcf Inhibitor, FH535;β-Catenin;β-catenin and PPAR
SMILES:	O=S(C1=CC(Cl)=CC=C1Cl)(NC2=CC=C([N+]([O-])=O)C=C2C)=O
Formula:	C13H10N2O4Scl2
M.Wt:	361.2005
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.
In Vivo:	FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts[2].
In Vitro:	FH535 is an inhibitor of Wnt/β-catenin and PPAR. FH535 inhibits PPARγ and PPARδ transactivation in HCT116 cells. FH535 (15 μM) activities depend on functional PPARδ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β-catenin to PPARδ and PPARγ. FH535 shows toxic effects on 12 carcinoma cell lines expressing wnt/β-catenin pathway[1]. FH535 (20 μM) suppresses the β-catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μM) inhibits pancreatic cancer cell invasion and cell growth[2]. FH535 represses angiogenesis-related genes in pancreatic cancer cells[3].